Q4 2025 Medistim ASA Earnings Call Transcript
Key Points
- Medistim ASA (STU:MD1) reported a record sales figure of NOK182.3 million for Q4 2025, marking a 20.6% growth compared to the previous year.
- The company's own products saw a significant sales increase of 25%, with the AMERICAS region leading with a 44.3% currency-neutral growth.
- Operating profit for Q4 2025 was strong at NOK42.3 million, up 63.8% from the same quarter last year, with an EBIT margin of 23.2%.
- For the full year 2025, Medistim ASA achieved nearly NOK700 million in revenues, reflecting a 24.4% growth, with own product sales growing by 28.3%.
- The Board proposed a dividend of NOK8 per share, totaling NOK146.2 million, reflecting the company's strong financial performance and cash position.
- The Asia Pacific region experienced a decline of 24.2% in sales for Q4 2025, indicating regional variability and challenges.
- The company faced a tariff expense of almost NOK4 million due to US tariffs, impacting the cost of goods sold.
- Salary and social expenses increased due to strengthening of the commercial and R&D teams, as well as higher commissions and bonuses.
- IT infrastructure expenses of NOK5.8 million negatively impacted the EBIT margin, which would have been higher without these costs.
- The transition to a cloud-based IT system resulted in certain expenses being expensed rather than capitalized, affecting financial results.
Good morning, everyone, and welcome to Medistim's fourth-quarter and preliminary financial results for 2025 presentation. My name is Kari Krogstad, and I'm joined with the CFO, Thomas Jakobsen. And we will go through this usual agenda, starting with the highlights.
And I'm very pleased to being able to report a new record for sales in the quarter, reaching NOK182.3 million in Q4. This means that we are continuing the high growth all through the year that we've seen in the first 3 quarters, ending with 20.6% growth in this fourth quarter.
We can see that there is quite a small currency effect when we are comparing to the currency in the same quarter last year. But still adjusting for that, the total sales will be -- could be 21.7%. And we're seeing that our own products are doing reallying well, and the sales is up 25%. And it is AMERICAS region that is really leading the way with 44.3% currency-neutral growth. We also see that EMEA, Europe, Middle East, and Africa, has a very strong quarter, this fourth quarter being up 24
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
